scholarly journals Cell Proliferation PET Imaging with 4DST PET/CT in Colorectal Adenocarcinoma and Adenoma

Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1658
Author(s):  
Ryogo Minamimoto ◽  
Hisako Endo
Keyword(s):  
Cell Proliferation ◽  
Sigmoid Colon ◽  
Colorectal Adenoma ◽  
Pet Imaging ◽  
Colorectal Adenocarcinoma ◽  
Tubular Adenoma ◽  
Positron Emission ◽  
Pet Ct ◽  
Descending Colon ◽  
Severe Type

An age of 70-year-old man was incidentally found two focal high 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) uptake in the descending colon and in the sigmoid colon. We observed the feature of these two areas in the preplanned 4′-[methyl-11C]-thiothymidine (4DST) positron emission tomography (PET)/computed Tomography (CT)providing cell proliferation imaging. A mass forming high 4DST uptake in the descending colon and focal moderate 4DST uptake in the sigmoid colon was confirmed, and that were proven pathologically as adenocarcinoma and moderate to severe type tubular adenoma, respectively. This is the first report to present that colorectal adenoma can be visualized by proliferation PET imaging and the degree of uptake may enable discrimination of colorectal adenoma from adenocarcinoma, based on pathological considerations.

scholarly journals PET Imaging of [11C]MPC-6827, a Microtubule-Based Radiotracer in Non-Human Primate Brains

Molecules ◽  
2020 ◽  
Vol 25 (10) ◽  
pp. 2289
Author(s):  
Naresh Damuka ◽  
Paul Czoty ◽  
Ashley Davis ◽  
Michael Nader ◽  
Susan Nader ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Neurological Disorders ◽  
Healthy Male ◽  
Time Activity ◽  
Positron Emission ◽  
Pet Ct ◽  
Scan Data ◽  
The Brain ◽  
Human Primate

Dysregulation of microtubules is commonly associated with several psychiatric and neurological disorders, including addiction and Alzheimer’s disease. Imaging of microtubules in vivo using positron emission tomography (PET) could provide valuable information on their role in the development of disease pathogenesis and aid in improving therapeutic regimens. We developed [11C]MPC-6827, the first brain-penetrating PET radiotracer to image microtubules in vivo in the mouse brain. The aim of the present study was to assess the reproducibility of [11C]MPC-6827 PET imaging in non-human primate brains. Two dynamic 0–120 min PET/CT imaging scans were performed in each of four healthy male cynomolgus monkeys approximately one week apart. Time activity curves (TACs) and standard uptake values (SUVs) were determined for whole brains and specific regions of the brains and compared between the “test” and “retest” data. [11C]MPC-6827 showed excellent brain uptake with good pharmacokinetics in non-human primate brains, with significant correlation between the test and retest scan data (r = 0.77, p = 0.023). These initial evaluations demonstrate the high translational potential of [11C]MPC-6827 to image microtubules in the brain in vivo in monkey models of neurological and psychiatric diseases.

scholarly journals Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3′-deoxy-3′[(18)F]-fluorothymidine, [(18)F]-FLT imaging and early response evaluation

2019 ◽  
Vol 12 (5) ◽  
pp. e218979 ◽  
Author(s):  
Kalevi Kairemo ◽  
Vivek Subbiah
Keyword(s):  
Positron Emission Tomography ◽  
Cell Proliferation ◽  
Proliferation Rate ◽  
Emission Tomography ◽  
Cardiac Tumours ◽  
Flt Pet ◽  
Cardiac Angiosarcoma ◽  
Pet Tracer ◽  
Positron Emission ◽  
Pet Ct

Primary cardiac angiosarcoma, the most common primary cardiac sarcoma has an incidence ranging from 0.001% to 0.028% in autopsy reports with around 200 cases reported in literature. Since a diagnosis of cardiac angiosarcoma portends a poor prognosis, it is vital to ascertain the precise extent of the lesions for follow-up. Imaging with positron emission tomography (PET) tracer 2-deoxy-2-[18F]-fluoro-D-glucose in cardiac angiosarcoma is challenging as myocardium takes up glucose and delineation of tumour becomes difficult. Cell proliferation rate in normal cardiac muscular tissue is low whereas cardiac tumours display a higher proliferation rate. This aspect could be exploited by use of 3′-deoxy-3′[(18)F]-fluorothymidine positron emission tomography (18F-FLT PET/CT] in cardiac tumours where the cell proliferation could be measured. Herein, we imaged an index case of cardiac angiosarcoma using18F-FLT PET/CT and report the findings.

scholarly journals [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity

2016 ◽  
Vol 113 (15) ◽  
pp. 4027-4032 ◽  
Author(s):  
Woosuk Kim ◽  
Thuc M. Le ◽  
Liu Wei ◽  
Soumya Poddar ◽  
Jimmy Bazzy ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Cytidine Deaminase ◽  
Cross Reactivity ◽  
Leukemia Cells ◽  
Deoxycytidine Kinase ◽  
Specificity And Sensitivity ◽  
Positron Emission ◽  
Pet Ct ◽  
Deoxyguanosine Kinase ◽  
Pet Probes

Deoxycytidine kinase (dCK), a rate-limiting enzyme in the cytosolic deoxyribonucleoside (dN) salvage pathway, is an important therapeutic and positron emission tomography (PET) imaging target in cancer. PET probes for dCK have been developed and are effective in mice but have suboptimal specificity and sensitivity in humans. To identify a more suitable probe for clinical dCK PET imaging, we compared the selectivity of two candidate compounds—[18F]Clofarabine; 2-chloro-2′-deoxy-2′-[18F]fluoro-9-β-d-arabinofuranosyl-adenine ([18F]CFA) and 2′-deoxy-2′-[18F]fluoro-9-β-d-arabinofuranosyl-guanine ([18F]F-AraG)—for dCK and deoxyguanosine kinase (dGK), a dCK-related mitochondrial enzyme. We demonstrate that, in the tracer concentration range used for PET imaging, [18F]CFA is primarily a substrate for dCK, with minimal cross-reactivity. In contrast, [18F]F-AraG is a better substrate for dGK than for dCK. [18F]CFA accumulation in leukemia cells correlated with dCK expression and was abrogated by treatment with a dCK inhibitor. Although [18F]CFA uptake was reduced by deoxycytidine (dC) competition, this inhibition required high dC concentrations present in murine, but not human, plasma. Expression of cytidine deaminase, a dC-catabolizing enzyme, in leukemia cells both in cell culture and in mice reduced the competition between dC and [18F]CFA, leading to increased dCK-dependent probe accumulation. First-in-human, to our knowledge, [18F]CFA PET/CT studies showed probe accumulation in tissues with high dCK expression: e.g., hematopoietic bone marrow and secondary lymphoid organs. The selectivity of [18F]CFA for dCK and its favorable biodistribution in humans justify further studies to validate [18F]CFA PET as a new cancer biomarker for treatment stratification and monitoring.

Use of FDG-PET Imaging for Patients with Disseminated Cancer of the Appendix

2010 ◽  
Vol 76 (12) ◽  
pp. 1338-1344 ◽  
Author(s):  
Payam Rohani ◽  
Stephen D. Scotti ◽  
Perry Shen ◽  
John H. Stewart ◽  
Gregory B. Russell ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Fdg Pet ◽  
Peritoneal Dissemination ◽  
Low Grade ◽  
High Grade ◽  
Positron Emission ◽  
Pet Ct ◽  
The Mean ◽  
Ct Data ◽  
Abdominal Quadrant

The goal of this study is to evaluate the use of positron emission tomography (PET) in evaluation of patients with peritoneal dissemination of carcinoma of appendiceal origin (PDA). Thirty-three patients with PDA, who had preoperative PET or PET/CT imaging, were analyzed. Using operative, pathology, and PET ± CT data, presence or absence of disease in each abdominal quadrant was noted and the use of 18fluoro-deoxy-glucose (FDG) PET for each quadrant was evaluated. The mean age was 52, and there were 17 males; 58 per cent had low-grade lesions. PET was positive in only 35 per cent of cases overall (30 and 41% sensitivity for low-grade and high-grade, respectively). PET without CT sensitivity for low-grade and high-grade lesions was 21 and 8 per cent, respectively. PET imaging has limited use for patients with PDA. We do not recommend the use of FDG-PET for patients with PDA from cancer of the appendix.

scholarly journals [18F]ML-10 Imaging for Assessment of Apoptosis Response of Intracranial Tumor Early after Radiosurgery by PET/CT

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Lu Sun ◽  
Kedi Zhou ◽  
Weijun Wang ◽  
Xiaojun Zhang ◽  
Zhongjian Ju ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Pet Imaging ◽  
Malignant Tumors ◽  
Human Subjects ◽  
Intracranial Tumor ◽  
Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
Before And After ◽  
Mri Scans

[18F]ML-10 is a novel apoptosis radiotracer for positron emission tomography (PET). We assess the apoptosis response of intracranial tumor early after CyberKnife (CK) treatment by [18F]ML-10 PET imaging. 29 human subjects (30 lesions), diagnosed with intracranial tumors, underwent CK treatment at 14–24 Gy in 1–3 fractions, had [18F]ML-10 positron emission tomography/computed tomography (PET/CT) before (pre-CK) and 48 hours after (post-CK) CK treatment. Magnetic resonance imaging (MRI) scans were taken before and 8 weeks after CK treatment. Voxel-based analysis was used for the imaging analysis. Heterogeneous changes of apoptosis in tumors before and after treatment were observed on voxel-based analysis of PET images. A positive correlation was observed between the change in radioactivity (X) and subsequent tumor volume (Y) (r=0.862, p<0.05), with a regression equation of Y=1.018∗X−0.016. Malignant tumors tend to be more sensitive to CK treatment, but the treatment outcome is not affected by pre-CK apoptotic status of tumor cells; [18F]ML-10 PET imaging could be taken as an assessment 48 h after CK treatment.

Development and Optimization of Zirconium-89 Production and Clinical TF-PET/CT Imaging Protocols for Breast Tumor Imaging and Immunotherapy Planning: A Review

2019 ◽  
Vol 9 (2) ◽  
pp. 215-222
Author(s):  
Khalid Alzimami
Keyword(s):  
Pet Imaging ◽  
Large Scale ◽  
Tumor Imaging ◽  
Scale Production ◽  
Imaging Protocols ◽  
Positron Emission ◽  
Large Scale Production ◽  
Pet Ct ◽  
Significant Interest ◽  
Potential Use

Zirconium-89 (89Zr) has recently drawn significant interest to be a promising metallo-radionuclide for use in immuno-PET due to favorable decay characteristics. Despite all efforts that have been done over the last few years in the development of procedures for large-scale production and purification of 89Zr and its stable coupling to mAbs as well as successful preclinical and clinical 89Zr immuno-positron emission tomography (PET) studies, there is still gap for exploring new peptide-based pharmaceuticals radiolabeled with 89Zr and the development of 89Zr immuno-PET imaging protocols. The objectives of this study is intended to review the recent development and optimization of 89Zr production and to discuss the 89Zr immuno-PET clinical imaging applications for breast cancer. In addition, the 89Zr PET imaging safety and protocols as well as the potential use of 89Zr in 3-gamma PET Imaging are reviewed.

scholarly journals Apoptotic PET Imaging of Rat Pulmonary Fibrosis With [18F]ML-8

2018 ◽  
Vol 17 ◽  
pp. 153601211879572 ◽  
Author(s):  
Ying Xiong ◽  
Dahong Nie ◽  
Shaoyu Liu ◽  
Hui Ma ◽  
Shu Su ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Pulmonary Fibrosis ◽  
Malonic Acid ◽  
Pet Imaging ◽  
Rat Model ◽  
Emission Tomography ◽  
Pathological Examination ◽  
Control Group ◽  
Positron Emission ◽  
Pet Ct

Objective: To investigate the value of 2-(3-[18F]fluoropropyl)-2-methyl-malonic acid ([18F]ML-8) positron emission tomography (PET) imaging of rat pulmonary fibrosis. Methods: Male Sprague-Dawley rats were divided into 2 groups, including pulmonary fibrosis model group and control group. The rat model was established by an intratracheal instillation of bleomycin (BLM). Control rats were treated with saline. Positron emission tomography/computed tomography (CT) with [18F]ML-8 or 18F-fluorodeoxyglucose ([18F]FDG) was performed on 2 groups. After PET/CT imaging, lung tissues were collected for histologic examination. Data were analyzed and comparisons between 2 groups were performed using Student t test. Results: Bleomycin-treated rats showed a higher lung uptake of [18F]ML-8 than control rats ( P < .05). In BLM-treated rats, the lung to muscle relative uptake ratio of [18F]ML-8 was also higher than that of [18F]FDG ( P < .05). Pathological examination showed overproliferation of fibroblasts and deposition of collagen in lungs from BLM-treated rats. Compared to control rats, BLM-treated rats had higher lung hydroxyproline content ( P < .05). Immunofluorescence staining indicated more apoptotic cells in BLM-treated rats than those in control rats. Moreover, the apoptosis rate of lung tissues obtained from BLM-treated rats was higher than that from control rats ( P < .05). Conclusions: 2-(3-[18F]fluoropropyl)-2-methyl-malonic acid PET/CT could be used for noninvasive diagnosis of pulmonary fibrosis in a rat model.

scholarly journals Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2153 ◽  
Author(s):  
Salvatore Annunziata ◽  
Daniele Antonio Pizzuto ◽  
Giorgio Treglia
Keyword(s):  
Prostate Cancer ◽  
Positron Emission Tomography ◽  
Pet Imaging ◽  
Diagnostic Performance ◽  
Emission Tomography ◽  
Cochrane Library ◽  
Evidence Based ◽  
Positron Emission ◽  
Pet Ct ◽  
Meta Analyses

A significant number of meta-analyses reporting data on the diagnostic performance of positron emission tomography (PET) in prostate cancer (PCa) is currently available in the literature. In particular, different PET radiopharmaceuticals were used for this purpose. The aim of this review is to summarize information retrieved by published meta-analyses on this topic. The first step included a systematic search of the literature (last search date: June 2020), screening two databases (PubMed/MEDLINE and Cochrane Library). This combination of key words was used: (A) “PET” OR “positron emission tomography” AND (B) “prostate” OR “prostatic” AND (C) meta-analysis. Only meta-analyses on Positron Emission Tomography/Computed Tomography (PET/CT) or Positron Emission Tomography/Magnetic Resonance (PET/MR) in PCa were selected. We have summarized the diagnostic performance of PET imaging in PCa, taking into account 39 meta-analyses published in the literature. Evidence-based data showed the good diagnostic performance of PET/CT with several radiopharmaceuticals, including prostate-specific membrane antigen (PSMA)-targeted agents, radiolabeled choline, fluciclovine, and fluoride in restaging and staging settings. Less evidence-based data were available for PET/MR with different radiotracers. More prospective multicentric studies and cost-effectiveness analyses are warranted.

scholarly journals Distinctive detection of insulinoma using [18F]FB(ePEG12)12-exendin-4 PET/CT

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Takaaki Murakami ◽  
Hiroyuki Fujimoto ◽  
Keita Hamamatsu ◽  
Yuki Yamauchi ◽  
Yuzo Kodama ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Detection Sensitivity ◽  
Neuroendocrine Neoplasms ◽  
Mouse Tumor ◽  
Post Injection ◽  
Imaging Evaluation ◽  
Insulinoma Cell ◽  
Positron Emission ◽  
Pet Ct

AbstractSpecifying the exact localization of insulinoma remains challenging due to the lack of insulinoma-specific imaging methods. Recently, glucagon-like peptide-1 receptor (GLP-1R)-targeted imaging, especially positron emission tomography (PET), has emerged. Although various radiolabeled GLP-1R agonist exendin-4-based probes with chemical modifications for PET imaging have been investigated, an optimal candidate probe and its scanning protocol remain a necessity. Thus, we investigated the utility of a novel exendin-4-based probe conjugated with polyethylene glycol (PEG) for [18F]FB(ePEG12)12-exendin-4 PET imaging for insulinoma detection. We utilized [18F]FB(ePEG12)12-exendin-4 PET/CT to visualize mouse tumor models, which were generated using rat insulinoma cell xenografts. The probe demonstrated high uptake value on the tumor as 37.1 ± 0.4%ID/g, with rapid kidney clearance. Additionally, we used Pdx1-Cre;Trp53R172H;Rbf/f mice, which developed endogenous insulinoma and glucagonoma, since they enabled differential imaging evaluation of our probe in functional pancreatic neuroendocrine neoplasms. In this model, our [18F]FB(ePEG12)12-exendin-4 PET/CT yielded favorable sensitivity and specificity for insulinoma detection. Sensitivity: 30-min post-injection 66.7%, 60-min post-injection 83.3%, combined 100% and specificity: 30-min post-injection 100%, 60-min post-injection 100%, combined 100%, which was corroborated by the results of in vitro time-based analysis of internalized probe accumulation. Accordingly, [18F]FB(ePEG12)12-exendin-4 is a promising PET imaging probe for visualizing insulinoma.

Sign in / Sign up

Export Citation Format

Share Document